These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1698481)

  • 1. Characterization of recombinant factor VIII and a recombinant factor VIII deletion mutant using a rabbit immunogenicity model system.
    Esmon PC; Kuo HS; Fournel MA
    Blood; 1990 Oct; 76(8):1593-600. PubMed ID: 1698481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F; Cannavò A; Garagiola I; Palla R; Mannucci PM; Rosendaal FR;
    J Thromb Haemost; 2018 Jan; 16(1):39-43. PubMed ID: 29080391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
    Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
    Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
    Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.
    Purohit VS; Middaugh CR; Balasubramanian SV
    J Pharm Sci; 2006 Feb; 95(2):358-71. PubMed ID: 16372314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
    Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
    Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII.
    Qu J; Ma C; Xu XQ; Xiao M; Zhang J; Li D; Liu D; Konkle BA; Miao CH; Li L; Xiao W
    PLoS One; 2020; 15(5):e0233576. PubMed ID: 32442215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superior in vivo response of recombinant factor VIII concentrate in children with hemophilia A.
    Kelly KM; Butler RB; Farace L; Cohen AR; Manno CS
    J Pediatr; 1997 Apr; 130(4):537-40. PubMed ID: 9108849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-depth comparison of N-glycosylation of human plasma-derived factor VIII and different recombinant products: from structure to clinical implications.
    Canis K; Anzengruber J; Garenaux E; Feichtinger M; Benamara K; Scheiflinger F; Savoy LA; Reipert BM; Malisauskas M
    J Thromb Haemost; 2018 Jun; ():. PubMed ID: 29888865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A.
    Ramani K; Miclea RD; Purohit VS; Mager DE; Straubinger RM; Balu-Iyer SV
    J Pharm Sci; 2008 Apr; 97(4):1386-98. PubMed ID: 17705286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.
    Purohit VS; Balasubramanian SV
    AAPS J; 2006 May; 8(2):E362-70. PubMed ID: 16796387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of recombinant human factor VIII (BAY w 6240) in the treatment of hemophilia A.
    Fukui H; Yoshioka A; Shima M; Tanaka I; Koshihara K; Fukutake K; Fujimaki M
    Int J Hematol; 1991 Oct; 54(5):419-27. PubMed ID: 1756252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.
    Kosloski MP; Miclea RD; Balu-Iyer SV
    AAPS J; 2009 Sep; 11(3):424-31. PubMed ID: 19499345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-Domain.
    Anzengruber J; Feichtinger M; Bärnthaler P; Haider N; Ilas J; Pruckner N; Benamara K; Scheiflinger F; Reipert BM; Malisauskas M
    Pharm Res; 2019 Apr; 36(5):77. PubMed ID: 30937539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
    Scharrer I; Ehrlich HJ
    Haemophilia; 2001 Jul; 7(4):346-8. PubMed ID: 11442637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice.
    Krishnamoorthy S; Liu T; Drager D; Patarroyo-White S; Chhabra ES; Peters R; Josephson N; Lillicrap D; Blumberg RS; Pierce GF; Jiang H
    Cell Immunol; 2016 Mar; 301():30-9. PubMed ID: 26775174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.